[Corrigendum] Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
Affiliations: Department of Oncology and Pathology, Karolinska University Hospital, SE‑171 76 Stockholm, Sweden, Department of Oncology, Rigshospitalet, 2100 Copenhagen, Denmark, Department of Oncology, Odense University Hospital, 5000 Odense, Denmark, Department of Radiology, Karolinska University Hospital, SE‑171 76 Stockholm, Sweden
- Published online on: April 24, 2017 https://doi.org/10.3892/ol.2017.6082
- Pages: 5035-5035
Copyright: © Holmsten et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Oncol Lett 12: [Related article:] 1293-1300, 2016; DOI: 10.3892/ol.2016.4775
Following the publication of this article, an interested reader drew to our attention that, on p. 1,298, the two curves in Fig. 2A and B show identical data. The Kaplan-Meier curves in Fig. 2, as published, both show the data for the median overall survival (mOS) curve, and not the mOS and median progression-free survival (mPFS) curves. Fig. 2A was intended to have shown the Kaplan-Meier curve for mPFS, and Fig. 2B the curve for mOS.
Survival data for patients with metastatic urothelial carcinoma treated with vinflunine as second-line chemotherapy, illustrated by Kaplan-Meier curves. (A) mPFS of 2.8 months (range, 0.5–34.3 months) and (B) mOS of 6.3 months (range, 0.3–39.7 months). mPFS, median progression-free survival; mOS, median overall survival.
A corrected version of Fig. 2, containing the correct data for mOS and mPFS, is shown below. This error did not affect the results or the conclusions reported in this study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. Furthermore, we regret any inconvenience this mistake has caused.